Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule Announces Management Team Changes
BURLINGTON, Mass. --(BUSINESS WIRE)--Mar. 15, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Robert Weiskopf , Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year. In conjunction with Mr.
View HTML
Toggle Summary ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Mar. 13, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence , President and Chief Operating Officer, and Brian Schwartz , MD, Chief Medical Officer and Head of Research and Development, of ArQule will present at Oppenheimer’s 29th Annual
View HTML
Toggle Summary ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Mar. 11, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in the 31st Annual ROTH Conference on March 17-19,
View HTML
Toggle Summary ArQule Reports Fourth Quarter and Full Year 2018 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)--Mar. 7, 2019-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the fourth quarter and full year of 2018. For the quarter ended December 31, 2018 , the Company reported a net loss of
View HTML
Toggle Summary ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome
Data support miransertib as a potential first systemic treatment for individuals affected by Proteus syndrome BURLINGTON, Mass. --(BUSINESS WIRE)--Feb. 25, 2019-- ArQule, Inc. (Nasdaq:ARQL), today announced the publication of clinical pharmacodynamic, safety and efficacy data in patients with
View HTML
Toggle Summary ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Feb. 21, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Brian Schwartz , M.D., Chief Medical Officer and Head of Research and Development, of ArQule will present at the 8th Annual Leerink Partners Global
View HTML
Toggle Summary ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Feb. 21, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019 . The Company will hold a conference call and webcast on the same day at
View HTML
Toggle Summary Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer
BURLINGTON, Mass. --(BUSINESS WIRE)--Jan. 24, 2019-- ArQule , Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking
View HTML
Toggle Summary Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA)
21% objective response rate with six confirmed partial responses from 29 evaluable patients 83% disease control rate Safety profile and tolerability of continuous dosing schedule confirmed BURLINGTON, Mass. --(BUSINESS WIRE)--Jan. 9, 2019-- ArQule , Inc.’s (Nasdaq: ARQL) partner, Basilea
View HTML
Toggle Summary ArQule Added to the NASDAQ Biotechnology Index
BURLINGTON, Mass. --(BUSINESS WIRE)--Dec. 19, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 24, 2018 .
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.